Literature DB >> 7028436

Metabolism and pharmacokinetics of the antibiotic rifampin.

M T Kenny, B Strates.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7028436     DOI： 10.3109/03602538109011084

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  43 in total

Review 1.  Tuberculosis in pregnancy and the puerperium.

Authors:  P Ormerod
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

2.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

3.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 4.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 5.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Authors:  Roger K Verbeeck; Bonifasius S Singu; Dan Kibuule
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 8.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

9.  Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

Authors:  Luis F López-Cortés; Rosa Ruiz-Valderas; Pompeyo Viciana; Aristides Alarcón-González; Jesús Gómez-Mateos; Eva León-Jimenez; Maria Sarasanacenta; Yolanda López-Pua; Jerónimo Pachón
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.